Vice President and Equity Research Analyst at William Blair Investment Management, LLC
Christine Reinsohn is a Vice President and Equity Research Analyst at William Blair, specializing in the coverage of healthcare and medtech sectors, with a focus on public companies within diagnostics, devices, and life sciences tools. She actively covers leading industry names such as Abbott Laboratories, Dexcom, Insulet, and several mid-cap medical technology firms, delivering actionable investment insights that have contributed to strong track records on platforms like TipRanks, where she has maintained a success rate of approximately 60% and favorable average returns on her published ratings. Christine began her equity research career after earning her MBA, joining William Blair in the mid-2010s following prior experience in finance and healthcare consulting. She holds FINRA Series 7, 63, 86, and 87 licenses and has been recognized internally and by industry peers for her analytic rigor and the impact of her sector calls.
Christine Reinsohn asked if ICON plc is still observing strength in early-phase work, as previously highlighted, or if there has been a shift towards late-phase work.
CEO Barry Balfe confirmed continued strong activity and double-digit growth in ICON plc's early-phase business on both a year-over-year and sequential basis, indicating an intention to sustain and improve this growth.
Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.
Trusted by leading investment firms and analysts